Onco Actu du 3 novembre 2016

	1. Biologie
Single-cell analysis supports a role for cancer stem cells in brain tumor growth [Massachusetts General Hospital] Mass. General, Broad Institute team finds strong evidence that cancer stem cells are important drivers of tumors in patients.
Science Snaps: understanding where breast cancer stems from [Cancer Research UK] In order to lift the veil on these elusive cells, scientists are retracing the steps a tumour takes as it develops, following it right back to where the cellular journey begins. And a handful of stunning images released this week reveal how researchers are beginning to piece together this journey for some types of breast cancer.
	3.1.1 Tabac - e-cigs
Some e-cig sweeteners may make toxic fumes at cigarette levels [Reuters] For the current study, researchers examined fumes released by e-cigarette liquids with different concentrations of three types of sugars, testing the vapor for levels of two toxins known as furans: 5-hydroxymethylfurfural (HMF) and furfural (FA), which have been linked to an increased risk of respiratory tract damage in humans and tumors in mice.
	4.10 Dép., diag. & prono. - Poumon
MD Anderson-led study develops prediction model for lung cancer risk in never smokers [MD Anderson] For this study, the researchers analyzed a prospective cohort of 395,875 participants in Taiwan, recruited by MJ Health Group to participate in a health-screening program across Taiwan.
	5.12 Immunothérapies
Exploring the promise and challenges of cancer immunotherapy [Stanford Medicine] Mackall is the lead investigator at Stanford for the new Parker Institute for Cancer Immunotherapy, launched earlier this year with a $250 million investment by entrepreneur and philanthropist Sean Parker.
Some immune-boosting cancer drugs may pose rare heart risks [STAT] “The problem is, no one has this on their radar,” so patients are not routinely checked for it, said Dr. Javid Moslehi, head of a Vanderbilt University clinic specializing in heart risks from cancer therapies.
Fulminant Myocarditis with Combination Immune Checkpoint Blockade [Now@NEJM] The manufacturer of these agents (Bristol-Myers-Squibb) reviewed the prevalence of myocarditis in their database of more than 20,000 patients and found that combination therapy resulted in myocarditis in 0.27% of cases and myositis in 0.24% of cases.
Lifesaving Cancer Drugs May in Rare Cases Threaten the Heart [NY Times] “It’s rare, but the fact that people have died from it is a reason for us to try to spare them that toxicity.”
	5.12.3 Immunothérapies-combinaisons
New Data Presentations at SITC 2016 Annual Meeting Highlight Bristol-Myers Squibb’s Leadership in Advancing the Science of Immuno-Oncology Combinations [BMS] Interim data evaluating the efficacy of lirilumab, an anti-KIR antibody, in combination with Opdivo (nivolumab), a PD-1 inhibitor, will be presented in a late-breaking oral session.
	5.2 Pharma
Tesaro Announces Submission of Niraparib New Drug Application for Platinum-Sensitive, Recurrent Ovarian Cancer [Tesaro] The niraparib NDA is supported by data from the ENGOT-OV16/NOVA trial, a double-blind, placebo-controlled, international Phase 3 study that enrolled 553 patients with recurrent ovarian cancer who were in response to their most recent platinum-based chemotherapy.
Oncolytic contender Turnstone bags a $41M B round to push a successor for Imlygic [EndPoints] Ever since Amgen made it to the market with a pioneering oncolytic virus cancer therapy called Imlygic (T-Vec), which it bagged in a billion-dollar deal to acquire BioVex, you could see a wave of biotech competitors forming — looking to do the same therapeutic job better.
On the ropes, Infinity gets a deal for duvelisib, with $0 up front as PI3k flounders [EndPoints] So this is where PI3k cancer drugs have fallen to. Infinity Pharmaceuticals, which once touted its lead drug duvelisib as a blockbuster contender, has now handed it over to the long suffering Verastem $VSTM for no money down and milestones that tap out at $28 million.
	5.2.1 Pharma - Partenariats
Here’s the Surprising Reason IBM Is Partnering With Celgene [Fortune] IBM Watson Health tries to do what no pharma company has done: solve the drug-safety puzzle.
	5.2.3 Pharma - économie
The backlash over high drug prices is hitting pharma where it hurts [STAT] “You can bet, over time, insurers will try to control the cost … for cancer care as well,” Porges said. “It’s going to be more difficult for payers to get their hands around oncology — but that being said, this is the fastest growing area of health spending, and they will certain try to implement ways to control cost.”
	5.4 Traitements - Economie
Life-extending breast cancer drug approved by NICE in draft guidance [NICE] Eribulin is recommended only if the company provides it with the discount agreed in the patient access scheme.
UK regulator approves drug that could extend lives of breast cancer patients [The Guardian] Breast cancer charities said the decision to make the drug routinely available in England could make a big difference to women whose breast cancer had proved resistant to other treatments.
Eisai latest cancer drugmaker to win UK approval after price cut [Reuters] The treatment, also known as eribulin, is the first new breast cancer medicine to be recommended by NICE in nearly a decade.
	6. Lutte contre les cancers
What's Next For Precision Medicine? [Fast Company] A panel of experts discuss the potential—and the potential pitfalls—of the medical model that proposes personalized, targeted health care.
Palliative care should be standard in cancer treatment: guideline [Reuters] For patients with advanced cancer, palliative care should start early and be an integral part of treatment, not just something added on near the end of life, according to a new practice guideline from the American Society for Clinical Oncology (ASCO).
Device Lets Cancer Patients Assist in their Own Breast Reconstruction, at Home [MIT Technology Review] Jeffrey Ascherman of the Columbia University Department of Surgery, who is principal investigator of the trial, says the device could represent the first major change in breast tissue expansion in 40 years.
	6.1 Observation
Current system unlikely to pick up surgeons with above average patient death rates [BMJ Blogs] Publishing the patient death rates of individual surgeons in England is unlikely to pick up those whose mortality rates are above average, because the caseload varies so much, concludes the first analysis of its kind published in the online journal BMJ Open.
	6.11 Patients
New U.S. Survey Sheds Light on the Experiences of People Caring for Someone Living with Lung Cancer [BMS] he results reveal that 92 percent of caregivers feel that caring for their loved one is a demanding experience, and nearly all (97%) caregivers report having had to change their lifestyle because of their loved one’s cancer. Conversely, 92 percent of respondents also describe their caregiving experience as rewarding.